Neuragen Science
A print-ready product information sheet is available in PDF format.
Neuragen Clinical Studies
Neuragen has been recommended by health care professionals in the USA and Canada since 1996 for the treatment of chronic pain associated with diabetic and other forms of peripheral neuropathy, shingles, fibromyalgia, post-surgical and accident induced nerve damage and other related conditions. Many patients have been successfully treated who have failed to respond to other common treatments.
Clinical Trials
Four clinical trials of Neuragen have been completed to date, with a
fifth trial in progress. In all trials to date, Neuragen provided rapid and effective pain relief without significant side effects.
LSU Clinical Trial Spring 2008
Sixty subjects with all cause neuropathic pain in the feet were treated
in a double blind placebo controlled trial by independent researchers
at Louisiana State University. The graph below represents the
percentage of people who experienced significant pain relief with
Neuragen vs placebo 30 minutes after application.
In a more detailed analysis, 52% of subjects treated with Neuragen
experienced at least a 50% reduction in pain within 30 minutes vs only
3% of the patients treated with a placebo.
Statistical analysis also revealed that the effects of the experimental
treatments were not affected by the usage of other pain analgesics for
neuropathy such as anti-convulsants and anti-depressants.
In a separate analysis of just the diabetics in the group, it was found
that the diabetics experienced the same pain relieving benefits as the
group as a whole.
LSU Clinical Trial Fall 2007
Forty subjects with all cause neuropathic pain in the feet were
treated in a double blind placebo controlled trial by independent
researchers at Louisiana State University. The graph below represents
the average pain level for all participants before treatment (time=0)
and for up to 9 hours after treatment with either Neuragen (blue drops)
or placebo (green triangles). Pain relief with Neuragen was
statistically significant over placebo and for up to 8 hours in
duration.
Another commonly accepted way to analyze data from pain trials is to
compare the number of patients who received at least a 50% reduction in
pain level vs. placebo. As shown on the left, 63% of subjects receiving
Neuragen benefited from a 50% or greater reduction in pain, vs. only
15% in the placebo group.
LSU Clinical Trial Fall 2006
In a separate clinical trial also done at Louisiana State University,
subjects with peripheral neuropathy received either Neuragen or no
treatment over a six week intervention, as part of a larger peripheral
neuropathy intervention study. Pain level was monitored on a 0-10 scale
three times every week, before treatment, after treatment, and after a
one-hour tai chi exercise session. As shown in the graph below, the
application of Neuragen significantly reduced pain levels within five
minutes and the pain relief lasted for at least one hour. Also noted
was that Neuragen treatment resulted in improved physical performance
and the ability to participate in tai chi exercises.
Diabetic Neuropathy Trial
People suffering with diabetic peripheral neuropathy with pain of at
least 3 months duration were invited to participate in an open label
trial of Neuragen for temporary pain relief. Subjects were recruited
from a California neuropathy support group, and instructed to apply
Neuragen topically to the maximally painful area at least six times in
one month, and complete one patient diary for each application.
Efficacy was measured primarily by reduction in pain intensity over the
first six hours, compared with the pain intensity before the
application. Overall, 29 patients satisfactorily completed the survey.
Of these, 20 patients (69%) noted some improvement in pain, with 17
patients (59%) noting a remarkable 50-100% improvement, usually within
minutes.
Repeated use of Neuragen decreased overall levels of pain for some
patients allowing them to use less medication overall. Also,
improvement in quality of life was associated with efficacy of Neuragen
including improved sleep, ability to work, social life, improved
energy, and a reduction in the tendency to depressed mood.
Clinical Use of Neuragen
Neuragen has been used effectively in a clinical setting by many health care professionals for the following indications:
- Diabetic peripheral neuropathies (Hand and foot pain)
- Post-Herpetic neuralgia (post-shingles pain)
- Chemotherapy induced peripheral neuropathy
- Reflex sympathetic dystrophies (RSD)
- Fibromyalgia
- Post-surgery or accident induced neuropathy
- Causalgias
- Radiculopathies
- Phantom limb pain
- Bell’s palsy
- Trigeminal neuralgias
- Mysofascial pain
- HIV neuropathic pain
- Sciatica / spinal compression
We recommend that you consult your health care professional about combining Neuragen with your current treatment. Ask your health care professional to request the results of these clinical studies.
Safety of Neuragen
The botanical oils and its fractions used in Neuragen have been a common ingredient in
foods and cosmetics for decades. In extensive clinical testing, the only detectable side effect
is minor skin irritation in a slight minority of patients with
sensitive skin. Please discontinue use if this occurs. There have been no reported adverse side effects when used according to directions. A flora aroma is pronounced due to the aromatic nature of the ingredients.
This information is not intended as medical advice. Its intention is solely educational. Please consult a medical or health professional for medical advice.
|
Products 
